Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1774 • ACR Convergence 2020
Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study
Nevena Rebic¹, Ria Garg², Sarah Munro², Glen Hazlewood³, Neda Amiri², Nick Bansback², Stephanie Ensworth², Corisande Baldwin⁴, Laurie Proulx⁵ and Mary De Vera¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Calgary, AB, Canada, ⁵Canadian Arthritis Patient Alliance, Ottawa, Canada
Background/Purpose: Despite guidelines for managing rheumatoid arthritis (RA) in pregnancy, high rates of discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) considered safe for women with RA…
Abstract Number: 0009 • ACR Convergence 2020
Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
Zakaria El Ouali¹, Elie Bassa¹, Abdoul-Rahamane Halidou Idrissa¹, Sarah Tazi¹, Samy Housbane², Mohamed Bennani Othmani², Kawtar Nassar¹ and Saadia Janani¹, ¹Department of Rheumatology, University Hospital of Ibn Rochd, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco, ²Medical Informatics Laboratory, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco
Background/Purpose: Antimalarial drugs (ADs), including chloroquine (CQ) and hydroxychloroquine (HCQ), have anti-inflammatory, immunomodulatory, antiparasitic, anti-thrombotic, and antiviral properties. Their indications in rheumatology have been known…
Abstract Number: 0239 • ACR Convergence 2020
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
Christina Charles-Schoeman¹, Sang-Cheol Bae², Arvind Chopra³, Stanley Cohen⁴, Jeffrey R Curtis⁵, Jacques-Eric Gottenberg⁶, Edward C Keystone⁷, Kunihiro Yamaoka⁸, Peter Nash⁹, J-Abraham Simon-Campos¹⁰, William Stohl¹¹, Michael Weinblatt¹², Rene Westhovens¹³, Jeff Siegel¹⁴, Iyabode Tiamiyu¹⁴, Lei Ye¹⁴, Deyuan Jiang¹⁴, Franziska Matzkies¹⁴, Angelika Jahreis¹⁴, John S. Sundy¹⁴ and Jon Giles¹⁵, ¹University of California, Los Angeles, Los Angeles, CA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Center for Rheumatic Diseases, Pune, India, ⁴University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia, ¹⁰Köhler & Milstein Research, Mérida, Mexico, ¹¹University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁴Gilead Sciences, Inc., Foster City, CA, ¹⁵Columbia University, New York, NY
Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and…
Abstract Number: 0607 • ACR Convergence 2020
The Evolution of Rheumatologist’s Practice in Response to the COVID19 Pandemic
Maria Bacalao¹, Kathryn Dao² and John Cush², ¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: The COVID19 pandemic was a turning point for Rheumatology. This survey of rheumatologists (rheums) assessed its impact on care delivery, patient counseling and drug…
Abstract Number: 0830 • ACR Convergence 2020
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 1047 • ACR Convergence 2020
Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab
Yan Li¹, Hassan Baig², Carlos Rojas², Justin Stowell², Elizabeth Lesser², Shalmali Borkar², Andy Abril¹ and Isabel Mira-Avendano¹, ¹Mayo Clinic, Ponte Vedra Beach, FL, ²Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases (CTDs) are commonly identified causes for interstitial lung disease (ILD). Compared with idiopathic interstitial pneumonias, patients with CTD-ILD and interstitial pneumonia…
Abstract Number: 1495 • ACR Convergence 2020
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Hermine I Brunner¹, Jonathan Akikusa², Eslam Al-Abadi², John Bohnsack³, Alina Lucica Boteanu², Gaelle Chedeville⁴, Ruben Cuttica², Wendy De La Pena⁴, Lawrence Jung⁴, Ozgur Kasapcopur², Katarzyna Kobusinska², Grant Schulert¹, Claudia Neiva², Rafael Rivas-Chacon⁴, Juan Cruz Rizo Rodriguez², Monica Vazquez-Del Mercado², Linda Wagner-Weiner⁴, Jennifer E Weiss¹, Carine Wouters², Ricardo M Suehiro⁵, Holly Posner⁶, Ann Wouters⁶, Keith S Kanik⁷, Zhen Luo⁸, Alberto Martini², Daniel J Lovell¹ and Nicolino Ruperto², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China (People's Republic)
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. We report the safety, tolerability, and efficacy of tofacitinib in patients (pts)…
Abstract Number: 1776 • ACR Convergence 2020
Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in Women with Systemic Lupus Erythematosus
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: The use of hydroxychloroquine (HCQ) has long been established in Systemic Lupus Erythematosus(SLE) and especially as applicable drug during pregnancy. Recently, beneficial effects and…
Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
David Simon¹, Koray Tascilar¹, Gerhard Krönke², Arnd Kleyer¹, Mario Zaiss³, Franz Heppt⁴, Christine Meder⁴, Raja Atreya⁵, Entcho Klenske⁵, Peter Dietrich⁵, Abdullah Abdullah⁵, Thorsten Kliem⁵, Giulia Corte⁶, Harriet Morf³, Moritz Leppkes⁵, Andreas Kremer⁵, Andreas Ramming³, Milena Pachowsky⁷, Florian Schuch⁸, Monika Ronneberger⁹, Stefan Kleinert¹⁰, Clara Maier¹¹, Axel Hueber¹², Karin Manger¹³, Bernhard Manger³, Carola Berking⁴, Matthias Tenbusch¹¹, Klaus Überla¹¹, Michael Sticherling³, Markus Neurath⁵ and Georg Schett¹⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Georgia, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Dermatology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Gibraltar, ⁷Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Rheumatology Clinical Practice Erlangen, Erlangen, Ghana, ⁹Rheumatology Clinical Practice Erlangen, Erlangen, Germany, ¹⁰Rheumatology-Nephrology Practice, Erlangen, Germany, ¹¹Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹²Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ¹³Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…
Abstract Number: 0359 • ACR Convergence 2020
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Soumya Chakravarty², Robert McLean³, Taylor Blachley³, Toana Kawashima⁴, Iris Lin⁵, Jonathan Uy⁶, Arthur Kavanaugh⁷ and Alexis Ogdie⁸, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Scientific Affairs, LLC, Horsham, ⁷UC San Diego Health System, San Diego, CA, ⁸Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…
Abstract Number: 0635 • ACR Convergence 2020
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
Bonnia Liu¹, Victor Yang², Christopher McMaster³, Russell Buchanan⁴, Albert Frauman⁵ and David Liew⁶, ¹Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, ²Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ⁶Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
Abstract Number: 0832 • ACR Convergence 2020
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Eugen Feist¹, Peer-Malte Aries², Silke Zinke³, Harald Burkhardt⁴, Inka Albrecht⁵, Oliver Bley⁵, Michael Obermeier⁶, Patrizia Sternad⁷, Martin Welcker⁷, Cornelia Kühne⁸, Ann-Dörthe Holst⁹, Niklas Thomas Baerlecken¹⁰ and Hans-Peter Tony¹¹, ¹Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ²Rheumatologie im Struenseehaus, Hamburg, Germany, ³Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, ⁴Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, ⁵Sanofi Aventis Deutschland GmbH, Berlin, Germany, ⁶GKM Gesellschaft für Therapieforschung, Munich, Germany, ⁷MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, ⁸Outpatient practice, Haldensleben, Germany, ⁹Outpatient practice, Ludwigslust, Germany, ¹⁰Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, ¹¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
Abstract Number: 1144 • ACR Convergence 2020
Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic
Michael George¹, Shilpa Venkatachalam², Shubhasree Banerjee¹, Joshua Baker¹, Peter Merkel¹, David Curtis³, Kelly Gavigan⁴, Maria (Maio) Danila⁵, Jeffrey R Curtis⁶ and William Nowell⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, ³Global Healthy Living Foundation, New York City, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham (UAB), Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Global Healthy Living Foundation, New York City, NY
Background/Purpose: Patients with autoimmune rheumatic diseases may be particularly concerned about COVID-19. We aimed to assess concerns and associated health behaviors of patients with autoimmune…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].